Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2002
12/19/2002WO2002100328A2 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002WO2002100327A2 Substituted 1-benzazepines and derivatives thereof
12/19/2002WO2002088144A3 ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-f]QUINOXALINE
12/19/2002WO2002087604A3 Preparations containing a combination of vitamin e and afamin
12/19/2002WO2002085906A3 Phthalazinones derivatives useful as pde4/7 inhibitors
12/19/2002WO2002085853A3 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
12/19/2002WO2002083651A3 Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
12/19/2002WO2002082075A9 Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
12/19/2002WO2002076388A3 Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside
12/19/2002WO2002074243A3 Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
12/19/2002WO2002070561A3 Nuclear hormone receptor ligand binding domain
12/19/2002WO2002070560A3 Nuclear hormone receptor ligand binding domain
12/19/2002WO2002070558A3 Nuclear hormone receptor ligand binding domain
12/19/2002WO2002070515A3 Chromane derivatives, process for their preparation and their use as antitumor agents
12/19/2002WO2002069972A3 Triazole compounds and the use thereof in the prophylaxis and therapy of neurodegenerative diseases, cerebral trauma and cerebral ischemia
12/19/2002WO2002064755A3 Post-partum mammalian placenta, its use and placental stem cells therefrom
12/19/2002WO2002060894A3 Sulfonamide lactam inhibitors of factor xa
12/19/2002WO2002060462A3 Waay to obtain a extract with antidepressant and opioid antagonists properties and pharmaceutical products obtained from it
12/19/2002WO2002060428A3 Methods of using and compositions comprising (-)sibutramine optionally in combination with other pharmacologically active compounds
12/19/2002WO2002059080A3 Trisubstituted carbocyclic cyclophilin binding compounds and their use
12/19/2002WO2002058626A9 Methods and compositions for the identification and treatment of neurodegenerative disorders
12/19/2002WO2002057222A3 Thiol-based naaladase inhibitors
12/19/2002WO2002056878A3 Pharmaceutical composition having reduced tendency for drug crystallization
12/19/2002WO2002055501A3 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them
12/19/2002WO2002042248A3 Naphthalene derivatives
12/19/2002WO2002029014A3 Stem cell differentiation-inducing promoter
12/19/2002WO2002024727A3 New inhibitors of iapp fibril formation and uses thereof
12/19/2002WO2002012269A3 Pharmaceutical composition comprising an analgesic peptide
12/19/2002WO2002011767A3 Methods for treating autoimmune and chronic inflammatory conditions using antagonists of cd30 or cd30l
12/19/2002WO2002005795A3 Pharmaceutical combinations for treatment and prevention of diabetes mellitus
12/19/2002WO2001077169A9 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
12/19/2002WO2001072977A9 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
12/19/2002WO2001068859A9 Il-17 receptor like molecules and uses thereof
12/19/2002WO2001047919A9 Substituted oxazolidinones and their use in the field of blood coagulation
12/19/2002WO2000058303A9 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
12/19/2002US20020193612 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
12/19/2002US20020193605 Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease
12/19/2002US20020193597 3-(heteroarylamino) indazole, 1,2-benzisothiazole, or 1,2-benzisoxazole derivatives of given formula; for treating nervous system disorders such as pain, anxiety and bipolar disorder
12/19/2002US20020193590 Tetra- or hexa-hydroazepine compounds substituted at the 4 position with benzofur-7-yl, indol-7-yl, or benzo(b)thiophen-7-yl; antidepressants
12/19/2002US20020193439 90-95% eicosapentaenoic acid (EPA) and < 5% of docosahexaenoic acid (DHA); treating psychiatric or central nervous disorders
12/19/2002US20020193438 Aripiprazole oral solution
12/19/2002US20020193433 Administering a patient a halogenated 2-phenyl-1,2-ethanediol dicarbamate enantiomer or enantiomeric mixture for the prevention or treatment of bipolar disorder
12/19/2002US20020193432 Useful as modulators of the interaction between the receptor for advanced glycated end product and its ligands
12/19/2002US20020193429 Methods for treating neuropsychiatric disorders
12/19/2002US20020193420 Neurotrophic, low molecular weight, small molecule heterocyclic ketone or thioester compounds are nonimmunosuppressive, has an affinity for FKBP type immunophilins
12/19/2002US20020193418 Methods of using and preparing thiolutin dioxide
12/19/2002US20020193409 Prodrugs of anticancer agents employing substituted aromatic acids
12/19/2002US20020193406 Novel compound
12/19/2002US20020193405 For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases
12/19/2002US20020193401 For therapy of depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder attention deficit disorder,obsessive compulsive disorder, obesity, eating disorders, sexual dysfunction
12/19/2002US20020193400 Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan
12/19/2002US20020193396 Sulfonamido ether substituted imidazoquinolines
12/19/2002US20020193378 Usable as tranquillisers and hypnotics
12/19/2002US20020193377 Quinazolines as MMP-13 inhibitors
12/19/2002US20020193367 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives
12/19/2002US20020193366 Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]-quinoline as 5-HT1A antagonists
12/19/2002US20020193365 Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists
12/19/2002US20020193364 For therapy of central nervous system (CNS) diseases
12/19/2002US20020193360 For enhancing cognition or in the treatment of diseases of cognitive dysfunction including but not limited to Alzheimer's Disease (AD), mild cognitive impairment, age-related cognitive decline, vascular dementia, Parkinson's disease
12/19/2002US20020193357 Liver X receptor agonists
12/19/2002US20020193317 Using smilagenin, prazerigenin, an astragaloside, tigogenin, ruscogenin, hecogenin and diosgenin in manufacture of medicament for therayp of condition characterised by deficiency in postsynaptic membrane-bound receptor number
12/19/2002US20020192826 Recombinant AAV vector-based transduction system and use of same
12/19/2002US20020192821 Increased functional activity and/or expression of ABC transporters protects against the loss of dopamine neurons associated with Parkinson's disease
12/19/2002US20020192801 Human uridine diphosphate galactose-4-epimerase
12/19/2002US20020192760 Nucleotide sequences coding membrane protein for use the diagnosis and treatment of asthma, parkinson's, heart defects, hypotension, urogenital disorders
12/19/2002US20020192758 C3b/C4b complement receptor-like molecules and uses thereof
12/19/2002US20020192749 Human polynucleotides, polypeptides, and antibodies
12/19/2002US20020192737 Detecting modulators of oxidoreductases; obtain sample, incubate with modulator, detect signal, monitor adjustment in enzyme activity
12/19/2002US20020192728 Neuroblastoma cell lines expressing the alpha2delta subunit of calcium channels and methods therefore
12/19/2002US20020192682 Polynucleotides and polypeptides of the IFNalpha-2 gene
12/19/2002US20020192305 Inflammatory mediation obtained from atractylodes lancea
12/19/2002US20020192290 Composition with sustained release of levodopa and carbidopa
12/19/2002US20020192288 Methods and compositions for treating pain of the mucous membrane
12/19/2002US20020192285 Controlled release pellet formulation
12/19/2002US20020192283 Odor-masking coating for a pharmaceutical preparation
12/19/2002US20020192277 Controlled release hydrocodone formulations
12/19/2002US20020192216 Therapeutic use
12/19/2002US20020192157 Treatment and diagnosis of macrophage mediated disease
12/19/2002DE10129940A1 Medicament used for treating central nervous system disorders e.g. psychosis, depression or neurological disorders, comprises new or known 4-phenylsulfonyl-oxazole-5-amine derivative which are serotonin 5-HT6 receptor ligands
12/19/2002CA2487039A1 Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases
12/19/2002CA2487038A1 Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
12/19/2002CA2450557A1 Substituted aminoalcohols useful in treatment of alzheimer's disease
12/19/2002CA2450384A1 Process for the production of zaleplon
12/19/2002CA2450366A1 Controlled heat induced rapid delivery of pharmaceuticals from skin depot
12/19/2002CA2450315A1 Dopamine receptor ligands and therapeutic methods based thereon
12/19/2002CA2450271A1 Novel phenylalkyl diamine and amide analogs
12/19/2002CA2450262A1 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators
12/19/2002CA2450205A1 Aminediols for the treatment of alzheimer's disease
12/19/2002CA2450202A1 Macrocycles useful in the treatment of alzheimer's disease
12/19/2002CA2450167A1 Macrocycles useful in the treatment of alzheimer's disease
12/19/2002CA2450113A1 Vanilloid receptor-related nucleic acids and polypeptides
12/19/2002CA2450027A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002CA2449987A1 Treatment of central neuropathic pain
12/19/2002CA2449957A1 Arylazo-substituted imidazole for the treatment of stress urinary incontinence
12/19/2002CA2449948A1 Methods of treating alzheimer's disease
12/19/2002CA2449934A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002CA2449673A1 Orally administered dosage forms of gaba analog prodrugs having reduced toxicity
12/19/2002CA2449654A1 Methods for treating disorders of the nervous and reproductive systems
12/19/2002CA2449649A1 A g-protein coupled receptor and uses therefor
12/19/2002CA2449629A1 Pyrrolidine derivatives as factor xa inhibitors
1 ... 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 ... 1833